GlaxoSmithKline has disclosed its second deal in less than a week designed to improve the analysis of genetic mutations in oncology. The latest collaboration is with GE Healthcare to establish a network of clinical laboratories to identify genetic mutations associated with specific tumor types.
In late 2014, the push to develop universal companion diagnostics to facilitate personal treatments for multiple cancers appears to be accelerating.
Diagnostics giant Thermo Fisher Scientific has partnered with GlaxoSmithKline and Pfizer to create a companion diagnostic for solid tumors that will address multiple drug programs. The move is a first step to superseding the often highly fragmented development and use of companion diagnostics to determine the best course of treatment for a particular patient.
The global companion diagnostics market crossed the billion-dollar threshold in 2013 and is continuing to climb rapidly as healthcare systems tap into the value of testing which patients would benefit most from targeted treatments.
Roche's Ventana Medical Systems is building a new distribution center in Arizona and plans to generate additional jobs in the process.
Tissue-based companion diagnostics company Flagship Biosciences said it will join with Sarepta Therapeutics to automate and quicken measurement of a key biomarker for muscular dystrophy.
Illumina has inked deals with three major Big Pharma companies with a goal of developing a universal gene-sequencing companion diagnostic test system focused on cancer.
Qiagen aims to develop new tests to target blood cancer patients who would benefit most from a particular treatment that hits a specific gene mutation. The plan could lead to new companion diagnostic tests for related drugs now under development.
Roche's Ventana Medical Systems will develop a companion diagnostic test with Germany's Merck KGaA that can be used for many different cancer types.
Roche is lending its diagnostic technology to Ferring Pharmaceuticals to develop a personalized treatment for female infertility.